Refine
Has Fulltext
- yes (21)
Is part of the Bibliography
- yes (21)
Document Type
- Journal article (21)
Language
- English (21)
Keywords
- ischemic stroke (7)
- B cells (3)
- ELISPOT (2)
- Inflammation (2)
- MS (2)
- Stroke (2)
- biomarker (2)
- chronic cerebrovascular disease (2)
- factor XII (2)
- immune cells (2)
- lymphocytes (2)
- platelets (2)
- predictive value (2)
- relapse (2)
- stroke (2)
- von Willebrand factor (2)
- Arterial water (1)
- Brain (1)
- Cardiac dysfunction| Brain natriuretic peptide (1)
- Coefficient (1)
- Experimental stroke (1)
- FXII (1)
- Glatiramer acetate (1)
- Heart failure (1)
- IL-15 (1)
- MIC ligands (1)
- Magnetic-resonance (1)
- Mice (1)
- NKG2D (1)
- NKG2D ligands (1)
- Neurodegeneration (1)
- Perfusion (1)
- Schlaganfall (1)
- Stim (1)
- T cell activation (1)
- Thrombus (1)
- Troponin (1)
- Vasodilatator-stimuliertes Phosphoprotein (1)
- Vasodilator-Stimulated Phosphoprotein (1)
- Von-Willebrand-factor (1)
- accuracy (1)
- acute ischemic stroke (1)
- adherence (1)
- atherosclerosis (1)
- atrial fibrillation (1)
- biomarkers (1)
- blood (1)
- blood coagulability (1)
- blood coagulation (1)
- cardiovascular disease (1)
- celiac disease (1)
- cerebral small vessel disease (1)
- cerebrovascular diseases (1)
- coagulation (1)
- cutting edge (1)
- demography (1)
- dendric cells (1)
- ejection fraction (1)
- expression (1)
- factor XI (1)
- feasibility (1)
- glycoprotein Ib (1)
- glycoprotein receptor Ib (1)
- guidelines (1)
- histology (1)
- human muscle-cells (1)
- hypercholesterolemia (1)
- idiopathic inflammatory myopathies (1)
- increased risk (1)
- inflammation (1)
- leukocytes (1)
- lymphokine-activated killer (1)
- mechanical thrombectomy (1)
- mechanisms (1)
- mice impact (1)
- monocytes (1)
- mouse model (1)
- multiple sclerosis (1)
- neuroinflammation (1)
- non-VKA oral anticoagulants (1)
- occlusion (1)
- pathology section (1)
- point-of-care echocardiography (1)
- polymorphisms inflammation (1)
- polymyositis (1)
- prevention (1)
- receptor (1)
- regulatory T cells (1)
- scale (1)
- sex addiction (1)
- stroke unit (1)
- systolic dysfunction (1)
- thrombo-inflammation (1)
- thromboinflammation (1)
- thrombus formation (1)
- transient ischemic attack (1)
- transient middle cerebral artery (1)
- transient middle cerebral artery occlusion (1)
- tumor immunity (1)
- vitamin K antagonists (1)
- warfarin (1)
Institute
- Neurologische Klinik und Poliklinik (19)
- Institut für Klinische Epidemiologie und Biometrie (5)
- Institut für Anatomie und Zellbiologie (3)
- Medizinische Klinik und Poliklinik I (3)
- Rudolf-Virchow-Zentrum (3)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (2)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (1)
- Institut für Experimentelle Biomedizin (1)
- Institut für Klinische Biochemie und Pathobiochemie (1)
- Neurochirurgische Klinik und Poliklinik (1)
Background:
Oral anticoagulant therapy (OAT) potently prevents strokes in patients with atrial fibrillation. Vitamin K antagonists (VKA) have been the standard of care for long-term OAT for decades, but non-VKA oral anticoagulants (NOAC) have recently been approved for this indication, and raised many questions, among them their influence on medication adherence. We assessed adherence to VKA and NOAC in secondary stroke prevention.
Methods:
All patients treated from October 2011 to September 2012 for ischemic stroke or transient ischemic attack with a subsequent indication for OAT, at three academic hospitals were entered into a prospective registry, and baseline data and antithrombotic treatment at discharge were recorded. At the 1-year follow-up, we assessed the adherence to different OAT strategies and patients' adherence to their respective OAT. We noted OAT changes, reasons to change treatment, and factors that influence persistence to the prescribed OAT.
Results:
In patients discharged on OAT, we achieved a fatality corrected response rate of 73.3% (n=209). A total of 92% of these patients received OAT at the 1-year follow-up. We observed good adherence to both VKA and NOAC (VKA, 80.9%; NOAC, 74.8%; P=0.243) with a statistically nonsignificant tendency toward a weaker adherence to dabigatran. Disability at 1-year follow-up was an independent predictor of lower adherence to any OAT after multivariate analysis, whereas the choice of OAT did not have a relevant influence.
Conclusion:
One-year adherence to OAT after stroke is strong (>90%) and patients who switch therapy most commonly switch toward another OAT. The 1-year adherence rates to VKA and NOAC in secondary stroke prevention do not differ significantly between both therapeutic strategies.